Viking Therapeutics (1VT) Price & Analysis

Compare

75 Followers

1VT Stock Chart & Stats

€26.94

-€0.26(-0.65%)

At close: Jan 08 4:00 PM EST

€26.94

-€0.26(-0.65%)

Day’s Range― - ―

52-Week Range€16.40 - €39.10

Previous CloseN/A

Volume0.00

Average Volume (3M)374.00

Market Cap

$3.17B

Enterprise Value€3.55B

Total Cash (Recent Filing)$705.74M

Total Debt (Recent Filing)$137.00K

Price to Earnings (P/E)―

Beta1.61

Next Earnings

Apr 29, 2026

EPS Estimate

-0.86

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.19

Shares Outstanding115,554,300

10 Day Avg. Volume144

30 Day Avg. Volume374

Financial Highlights & Ratios

PEG Ratio-0.05

Price to Book (P/B)6.20

Price to Sales (P/S)0.00

P/FCF Ratio-14.22

Enterprise Value/Market Cap1.12

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-37.75K

Enterprise Value/Ebitda-9.03

Forecast

1Y Price Target

$79.98

Price Target Upside196.87% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering12

EPS Forecast (FY)-3.58

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Analyst Coverage And RatingsAnalyst reiterates a Buy rating on Viking Therapeutics, signaling continued confidence from coverage and supporting positive investor sentiment.

Cash Position And Manufacturing ReadinessA strong cash balance combined with confidence in manufacturing capacity for oral and auto-injector formats should fund pivotal programs and lower near-term dilution risk.

Clinical Development ProgressAdvancement of both oral and injectable VK2735 into late-stage trials alongside a fully enrolled maintenance dosing study increases the likelihood of pivotal data readouts and potential regulatory filings.

Bears Say

Clinical Outcome DependencyAnalyst's investment case is contingent on maintenance trial results, creating binary clinical risk that could produce sharp stock volatility based on trial outcomes.

Competition And Manufacturing ChallengesPersistent manufacturing hurdles and intense competition in the obesity market could limit commercial uptake and cap potential market share even with clinical success.

Financial Performance And Funding RiskHigher research and development spending has widened losses and reported financial results missed expectations, heightening the need for additional funding and pressuring sentiment.

Viking Therapeutics News

Viking Therapeutics management to meet with Truist

Meeting to be held in Chicago on March 3 and in Denver on March 4 hosted by Truist....

2d ago

VKTX

Viking Therapeutics rises 10.7%

Viking Therapeutics (VKTX) is up 10.7%, or $3.33 to $34.36. Published first on TheFly – the ultimate source...

10d ago

VKTX

Unusually active option classes on open February 23rd

Unusual total active option classes on open include: Vanda (VNDA), Grail Inc (GRAL), Frontline (FRO), Viking Therapeutics (VKTX),...

10d ago

FRO

SLS

Here is a List of Small-Cap Biotech ETFs to Watch for Big Gains in 2026

Biotech ETFs are regaining attention as analyst targets signal renewed upside heading into 2026, particularly among small- and...

14d ago

BIB

CRBU

Viking Therapeutics price target lowered to $99 from $102 at Morgan Stanley

Morgan Stanley analyst Michael Ulz lowered the firm’s price target on Viking Therapeutics (VKTX) to $99 from $102...

21d ago

VKTX

These Are the Stocks Reporting Earnings Today – February 12, 2026

Here’s a look at today’s key earnings reports from major publicly traded companies. Stock market investors will undoubtedly...

21d ago

BUD

Viking Therapeutics reports Q4 EPS ($1.38), consensus (90c)

At December 31, 2025, Viking held cash, cash equivalents and short-term investments of $706M, compared to $903 M...

22d ago

VKTX

Viking Therapeutics options imply 9.5% move in share price post-earnings

Pre-earnings options volume in Viking Therapeutics (VKTX) is normal with calls leading puts 6:1. Implied volatility suggests the...

22d ago

VKTX

Options Volatility and Implied Earnings Moves This Week, February 10 – February 13, 2026

This week, several major companies will be reporting earnings. Among them are Coca-Cola (KO), Ford Motor (F), Shopify...

24d ago

Maintained Buy Rating on Viking Therapeutics Reflects Confidence in Pipeline Strength and Favorable Risk‑Reward Profile

Jeet Mukherjee, an analyst from BTIG, reiterated the Buy rating on Viking Therapeutics. The associated price target is...

8d ago

VKTX

Viking Therapeutics Surges as Obesity Drug Hopes Rise

Viking Therapeutics ( ($VKTX) ) has risen by 7.24%. Read on to learn why. Viking Therapeutics’ share price...

12d ago

VKTX

Viking Therapeutics Bets Big on Obesity Breakthroughs

Viking Therapeutics (($VKTX)) has held its Q4 earnings call. Read on for the main highlights of the call....

21d ago

VKTX

VKTX Earnings this Week: How Will it Perform?

Viking Therapeutics (VKTX) is scheduled to report 4th quarter earnings on 02/12/2026, before the market opens. Regarding Q4...

23d ago

VKTX

Viking Therapeutics management to meet virtually with Oppenheimer

Virtual Meeting to be held on January 22 hosted by Oppenheimer. Published first on TheFly – the ultimate...

1M ago

VKTX

1VT FAQ

What was Viking Therapeutics’s price range in the past 12 months?

Viking Therapeutics lowest stock price was €16.40 and its highest was €39.09 in the past 12 months.

What is Viking Therapeutics’s market cap?

Viking Therapeutics’s market cap is $3.17B.

When is Viking Therapeutics’s upcoming earnings report date?

Viking Therapeutics’s upcoming earnings report date is Apr 29, 2026 which is in 55 days.

How were Viking Therapeutics’s earnings last quarter?

Viking Therapeutics released its earnings results on Feb 11, 2026. The company reported -€1.187 earnings per share for the quarter, missing the consensus estimate of -€0.765 by -€0.421.

Is Viking Therapeutics overvalued?

According to Wall Street analysts Viking Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Viking Therapeutics pay dividends?

Viking Therapeutics does not currently pay dividends.

What is Viking Therapeutics’s EPS estimate?

Viking Therapeutics’s EPS estimate is -0.86.

How many shares outstanding does Viking Therapeutics have?

Viking Therapeutics has 115,554,300 shares outstanding.

What happened to Viking Therapeutics’s price movement after its last earnings report?

Viking Therapeutics reported an EPS of -€1.187 in its last earnings report, missing expectations of -€0.765. Following the earnings report the stock price went up 15.306%.

Which hedge fund is a major shareholder of Viking Therapeutics?

Currently, no hedge funds are holding shares in DE:1VT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Viking Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-47.34%

Trailing 12-Months

Asset Growth

-21.20%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Viking Therapeutics

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Viking Therapeutics (1VT) Earnings & Revenues

Historic Earnings Reports

1VT Earnings Call

Q4 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call emphasized substantial clinical and operational progress: compelling Phase II efficacy for both subcutaneous (up to 14.7%) and oral (up to 12.2%, with 80% ≥10% responders), initiation and fast enrollment of Phase III programs, completion of auto-injector bioequivalence enabling device rollout, a completed maintenance study enrollment with results expected Q3 2026, a manufacturing agreement to support commercialization, and expansion of the pipeline with an amylin agonist. Offsetting these positives are sharply higher R&D expenses and widening net losses (large YoY increases), a ~22% decline in cash year-over-year, and a projected quarterly burn of $60M–$90M, alongside marketplace and reimbursement uncertainties. On balance, the operational and clinical milestones materially outweigh the financial and market risks presented on the call.View all DE:1VT earnings summaries

1VT Stock 12 Month Forecast

Average Price Target

€79.98

▲(196.87% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"21":"€21","108":"€108","42.75":"€42.8","64.5":"€64.5","86.25":"€86.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":107.49507249999999,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€107.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":79.97633394,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€79.98</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":60.1972406,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€60.20</span>\n  </div></div>","useHTML":true}}],"tickPositions":[21,42.75,64.5,86.25,108],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.48,34.5580825,40.636165,46.7142475,52.79232999999999,58.8704125,64.948495,71.02657749999999,77.10466,83.18274249999999,89.260825,95.33890749999999,101.41698999999998,{"y":107.49507249999999,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.48,32.44125645692308,36.40251291384615,40.36376937076923,44.32502582769231,48.28628228461538,52.24753874153846,56.20879519846154,60.17005165538461,64.13130811230769,68.09256456923077,72.05382102615384,76.01507748307692,{"y":79.97633394,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.48,30.91978773846154,33.35957547692308,35.799363215384616,38.239150953846156,40.678938692307696,43.11872643076923,45.55851416923077,47.99830190769231,50.43808964615385,52.87787738461539,55.31766512307692,57.75745286153847,{"y":60.1972406,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":27.9,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.35,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.8,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.68,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.005,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.1,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.495,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.19,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.6,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.51,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.555,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.2,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.48,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >